首页> Journal of the American Academy of Dermatology> Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

导出原文传递

翻译打印收藏纠错

第一作者： Amy S,Paller

第一单位： Northwestern University, Feinberg School of Medicine, Chicago, Illinois. Electronic address: APaller@nm.org.

作者： Amy S,Paller ^[1] ; Wynnis L,Tom ^[2] ; Mark G,Lebwohl ^[3] ; Robin L,Blumenthal ^[4] ; Mark,Boguniewicz ^[5] ; Robert S,Call ^[6] ; Lawrence F,Eichenfield ^[2] ; Douglass W,Forsha ^[7] ; William C,Rees ^[8] ; Eric L,Simpson ^[9] ; Mary C,Spellman ^[4] ; Linda F,Stein Gold ^[10] ; Andrea L,Zaenglein ^[11] ; Matilda H,Hughes ^[4] ; Lee T,Zane ^[4] ; Adelaide A,Hebert ^[12]

作者单位： Northwestern University, Feinberg School of Medicine, Chicago, Illinois. Electronic address: APaller@nm.org. ^[1] Rady Children's Hospital-San Diego, San Diego, California; University of California, San Diego, La Jolla, California. ^[2] Icahn School of Medicine at Mount Sinai, New York, New York. ^[3] Anacor Pharmaceuticals, Inc, Palo Alto, California. ^[4] National Jewish Health, Denver, Colorado; University of Colorado School of Medicine, Denver, Colorado. ^[5] Clinical Research Partners, Richmond, Virginia. ^[6] Jordan Valley Dermatology and Research Center, West Jordan, Utah. ^[7] Pi-Coor Clinical Research, Burke, Virginia. ^[8] Oregon Health and Science University, Portland, Oregon. ^[9] Henry Ford Health System, Detroit, Michigan. ^[10] Pennsylvania State University, Hershey, Pennsylvania. ^[11] University of Texas Health Science Center Houston, Houston, Texas. ^[12]

关键词 atopic dermatitis crisaborole ointment eczema phosphodiesterase 4 pruritus topical therapy